The potential role of nitric oxide in the hypertrophic growth of the left ventricle

Physiological Research

Volumn 49, Issue 1, 2000, Pages 37-46

  Simko F ^a   Simko J ^b  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b FACULTY HOSPITAL   (Slovakia)

Author keywords

Angiotensin II; Cardiac hypertrophy; L NAME; Nitric oxide

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; BRADYKININ ANTAGONIST; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; ICATIBANT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OLMESARTAN; TEMOCAPRIL; VASODILATOR AGENT;

ENZYME INHIBITION; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; VASCULAR ENDOTHELIUM;

ANIMALS; ARGININE; ENZYME INHIBITORS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 0033956274     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (92)

1. AKUZAWA N, NAKAMURA T, KURASHINA T, SAITO Y, HOSHINI J, SAKAMOTO H, SUMINO H, ONO Z, NAGAI R: Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis. Am J Hypertens 11: 697-707, 1998.
2. ANDERSON NH, DEVLIN AM, GRAHAM D, MORTON JJ, HAMILTON CA, REIDL JL, SCHORK NJ, DOMINICZAK AF: Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis. Hypertension 33: 248-255, 1999.
3. ARNAL JF, WARIN L, MICHEL JB: Determination of aortic cyctic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 90: 647-652, 1992.
4. BABÁL P, PECHÁŇOVÁ O, BLRNÁTOVÁ I, ŠTVRTINA S: Chronic inhibition of NO synthesis produces myocardial ilbrosis and vascular medial hyperplasia. Histol Histopathol 12: 623-629, 1997.
5. BANTING JD, THOMPSON KE, FRIBERG P, ADAMS MA: Blunted cardiovascular growth induction during prolonged nitric oxide synthase blockade. Hypertension 30: 416-421, 1997.
6. BARTUNEK J, DEMPSEY S, WEINBERG EO, ITO N, TAJIMA M, ROHRBACH S, LORELL BH: Chronic L-arginine treatment increases cardiac cyclic guanosine 5 monophosphate in rats with aortic stenosis: effects of left ventricular mass and beta-adrenergic contractile reserve. J Am Coll Cardiol 32: 528-535, 1998.
7. BAYLIS CH, MITRUKA B, DENG A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992.
8. BERNÁTOVÁ I, PECHÁŇOVÁ O, ŠIMKO F: Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. Physiol Res 45: 311-316, 1996.
9. BERNÁTOVÁ I, PECHÁŇOVÁ O, ŠIMKO F: Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney. Exp Physiol. 84: 1095-1105, 1999a.
10. BERNÁTOVÁ I, PECHÁŇOVÁ O, KRISTEK F: Metabolic and structural remodelling of the rat aorta during long-term L-NAME treatment. Jpn J Pharmacol 81: 99-106, 1999b.
11. CHEN PY, SANDERS PW: L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 88: 1559-1567, 1991.
12. G-monomethyl-L-arginine of vasodilator effects of acetylcholine and methacholine in human forearm vasculature. Br J Pharmacol 110: 736-738, 1993.
13. CRABOS M, COSTE P, PACCALIN M, TARIOSSE L, DARET D, BESSE P, BONORON-ADEEE S: Reduced basal NO-mediated dilation and decreased endothelial NO-synthase expression in coronary vessels of spontaneously hypertensive rats. J Mol Cell Cardiol 29: 55-65, 1997.
14. DEVLIN AM, BROSNAN MJ, GRAHAM D, MORTON JJ, MCPHADEN AR, MCINTYRE M, HAMILTON CA, REID JL, DOMINICZAK AF: Vascular smooth muscle cell polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in vivo. Am J Physiol 274: H52-H59, 1998.
15. DOMINICZAK AF, BOHR DF: Nitric oxide and its putative role in hypertension. Hypertension 25: 1202-1211, 1995.
16. DUSTING GJ, MACDONALD PS: Endogenous nitric oxide in cardiovascular disease and transplantation. Ann Med 27: 395-406, 1995.
17. FÍZEL'OVÁ A, FÍZEL A: Cardiac hypertrophy and heart failure: dynamics of changes in proteins and nucleic acids. J Mol Cell Cardiol 1: 389-402, 1971.
18. FÖRSTERMANN U, POLLOCK JS, SCHMIDT HH, HELLER M, MURAD F: Calmodulin dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA 88: 788-792, 1991.
19. FORTE P, COPLAND M, SMITH LM, MILNE E, SUTHERLAND J, BENJAMIN N: Basal nitric oxide synthesis in essential hypertension. Lancet 349: 837-842, 1997.
20. FROHLICH ED: Overview of hemodynamic and non-hemodynamic factors associated with left ventricular hypertrophy. J Mol Cell Cardiol 21: 3-10, 1989.
21. FUJITA H, TAKEDA K, NAKAMURA K, UCHIDA A, TAKENAKA K, ITOH H, NAKATA T, SASAKI S, NAKAGAWA M: Role of nitric oxide in impaired coronary circulation and improvement by angiotensin II receptor antagonist in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 22: 148-150, 1995.
22. GARG UC, HASSID A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosinc monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83: 1774-1777, 1989.
23. GEROVÁ M, PECHÁŇOVÁ O, BERNÁTOVÁ I, KITTOVÁ M, JURÁNI M: Early changes of protein synthesis in myocardium and coronary arteries induced by NO synthase inhibition. Physiol Res 47: 405-412, 1998.
24. HASEGAWA T, TAKAGI S, NISHIMAKI K, MORITA K, NAKAJIMA S: Impairment of L-arginine metabolism in spontaneously hypertensive rats. Biochem Int 26: 653-658, 1992.
25. HAYAKAWA H, RAIJ L: The link among nitric oxide synthase activity, endothelial function, and aortic and vetricular hypertrophy in hypertension. Hypertension 29: 235-241, 1997.
26. HOLÉCYOVÁ A, GEROVÁ A, KRISTEK F, KLASOVÁ A, ŠIMKO F: Long term increase in preload compromises the responsiveness of coronary and systemic arteries differently. J Mol Cell Cardiol 27: A90, 1995.
27. HOLÉCYOVÁ A, TÖRÖK J, BERNÁTOVÁ I, PECHÁŇOVÁ O: Restriction of nitric oxide rather than elevated blood pressure is responsible for alterations of vascular responses in nitric oxide deficient hypertension. Physiol Res 43: 317-321, 1996.
28. HROPOT M, GROTSCH H, KLAUS E, LANGER KH, LINZ W, WIEMER G, SCHÖLKENS BA: Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency. Naunyn-Schmiedeberg's Arch Pharmacol 350: 646-652, 1994.
29. KANEKO H, ENDO T, KIUCHI K, KAYAKAWA H: Inhibition of nitric oxide synthesis reduces coronary blood flow response but does not increase cardiac contractile response to beta-adrenergic stimulation in normal dogs. J Cardiovasc Pharmacol 27: 247-254, 1996.
30. KOLPAKOV V, GORDON D, KULIK TJ: Nitric-oxide generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res 76: 305-309, 1995.
31. KRISTEK F: Long-term administration of L-arginine did not influence blood pressure, heart rate, cardiac hypertrophy or arterial wall thickness of spontaneously hypertensive rats. Exp Physiol 83: 595-603, 1998.
32. KRISTEK F, GEROVÁ M, DEVÁT L, VARGA I: Remodeling of septal branch of coronary artery and carotid artery in L-NAME treated rats. Physiol Res 45: 329-333, 1996.
33. KUO JF, DAVIS SV, TSE J: Depressed cardiac cyclic GMP-dcpcndent protein kinase in spontaneously hypertensive rats and its further depression by guanethinidine. Nature 261: 335-336, 1976.
34. K-LAFLAMME A, OSTER L, CARDINAL R, DE CHAMPLAIN J: Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate- salt hypertension. Can J Physiol Pharmacol 76: 665-675, 1998.
35. LINZ W, WIEMER G, GOHLKE P, UNGER T, SCHÖLKENS BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47: 25-49, 1995.
36. ω-nitro-L-arginine methyl ester affects blood pressure and cardiovascular structure in the genetically hypertensive rat strain. Clin Exp Pharmacol Physiol 24: 433-435, 1997.
37. LÜSCHER TF: The endothelium. Target and promoter of hypertension? Hypertension 15: 482-485, 1990.
38. LÜSCHER TF, RAIJ L, VANHOUTTE PM: Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension 9: 157-163, 1987.
39. MANDARIM-DE-LACERDA CA, PEREIRA LMM: Stereology of the myocardium in hypertensive rats under chronic inhibition of nitric oxide synthesis. Biomed Res 8: 153-160, 1997.
40. MATSUBARA BB, MATSUBARA LS, ZORNOFF LA, FRANCO M, JANICKI JS: Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats. Basic Res Cardiol 93: 173-81, 1998.
41. MATSUOKA H, NAKATA M, KEISUKE KOHNO, KOGA Y, NOMURA G, TOSHIMA H, IMAIZUMI T: Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 27: 14-18, 1996.
42. MAYHAN WG: Impairment of endothelium-dependent dilatation of basilar artery during chronic hypertension. Am J Physiol. 259: H1455-H1462, 1990.
43. G-nitro L-arginine methyl ester due to converting enzyme inhibition. J Cardiovasc Pharmacol 28: 142-148, 1996.
44. MORENO H Jr, PIOVESAN NATHAN L, PEREIRA COSTA SK, METZE K, ANTURES E, ZATZ R, DE NUCCI G: Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis. Eur J Pharmacol 287: 93-96, 1995.
45. MORENO H Jr, METZE K, BENTO AC, ANTUNES E, ZATZ R, DE NUCCI G: Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res Cardiol 91: 248-255, 1996.
46. NAKAKI T, HISHIKAWA K, SUZUKI H, SARUTA T, KATO R: L-arginine induced hypotension. Lancet 336: 696, 1990.
47. A receptor antagonist ameliorates nephrosclerosis and left ventricular hypertrophy induced in rat by prolonged inhibition of nitric oxide synthesis. Hypertens Res 21: 251-257, 1998.
48. NISHIDA Y, DING J, ZHOU MS, CHEN QH, MURAKAMI H, WU XZ, KOSAKA H: Role of nitric oxide in vascular hyper-responsiveness to norepinephrine in hypertensive Dahl rats. J Hypertens 16: 1611-1618, 1998.
49. NUMAGUCHI K, EGASHIRA K, TAKEMOTO M, KADOKAMI T, SHIMOKAWA H, SUEISHI K, TAKESHITA A: Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 26: 957-962, 1995.
50. OKRUHLICOVÁ L, TRIBULOVÁ N, BERNÁTOVÁ I, PECHÁŇOVÁ O: Induction ofangiogenesis in NO-deficient rat heart. Physiol Res 49: 000-000, 2000. (this issue)
51. PACKER M., BRISTOW MR, COHN JN, COLUCCI WS, FOWLER MB, GILBERT EM, SHUSTERMAN NH: The effect of carvedilol on morbidity and mortality of patients with chronic heart failure. N Engl J Med 334: 1349-1355, 1996.
52. PALMER RMJ, ASHTON DS, MONCADA S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664-666, 1988.
53. PECHÁŇOVÁ O, BERNÁTOVÁ I: Effect of long-term NO synthase inhibition on cyclic nucleotide content in rat tissues. Physiol Res 45: 305-309, 1996.
54. PECHÁŇOVÁ O, BERNÁTOVÁ I: Effect of long term nitric oxide synthase inhibition in rat cardiovascular system. Exp Clin Cardiol 3: 151-157, 1998.
55. PECHÁŇOVÁ O, BERNÁTOVÁ I: Effect of captopril on cyclic nucleotide concentrations during long-term NO synthase inhibition. Physiol Res 49: 000-000, 2000. (this issue)
56. PECHÁŇOVÁ O, BERNÁTOVÁ I, PELOUCH V, ŠIMKO F: Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol 29: 3365-3374, 1997.
57. PECHÁŇOVÁ O, BERNÁTOVÁ I, PELOUCH V, BABÁL P: L-NAME induced protein remodeling and fibrosis in the rat heart. Physiol Res 48: 353-362, 1999.
58. PELOUCH V, DIXON IMC, SETHI R, DHALLA NS: Role of extracellular matrix proteins in heart function. Mol Cell Biochem 4: 101-120, 1994.
59. PELOUCH V, KOLÁŘ F, OŠŤÁDAL B, MILEROVÁ M, ČIHÁK R, WIDIMSKÝ J: Regression of chronic hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, and fibrosis: effect of enalapril. Cardiovasc Drug Ther 11: 177-185, 1997.
60. PEREIRA LMM, MANDARIM-DE-LACERDA CA: Quantitative examination of the cardiac myocytes in hypertensive rats under chronic inhibition of nitric oxide synthesis. J Biomed Sci 5: 363-369, 1998.
61. PEREIRA LMM, VIANNA GMM, MANDARIM-DE-LACERDA CA: Stereology of the myocardium in hypertensive rats. Differences in relation to the time of inhibition of nitric oxide synthesis. Virchows Arch 443: 369-373, 1998.
62. PEREIRA LMM, MANDARIM-DE-LACERDA CA: Myocardial microcirculation stereological changes in rats subjected to nitric oxide synthesis inhibition. Pathol Res Pract 195: 177-181, 1999.
63. PESSANHA MG, MANDARIM-DE-LACERDA CA, DUMAS HAHN M: Stereology and immunohistochemistry of the myocardium in experimental hypertension: long-term and low-dosage administration of inhibitor of the nitric oxide synthesis. Pathobiology 67: 26-33, 1999.
64. POLLOCK DM, POLAKOWSKI JS, DIVISH BJ, OPGENORLH TJ: Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 21: 660-666, 1993.
65. RAIJ L: Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension 31: 189-193, 1998.
66. RHALEB NE, YANG XP, SCICLI G., CARRETERO OA: Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension 23: 865-868, 1994.
67. RIBEIRO MO, ANTUNES E, DE NUCCI G, LOVISOLO SM, ZATZ R: Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension 20: 298-303, 1992.
68. RITCHIE RH, SCHIEBINGER RJ, LAPOINTE MC, MARSH JD: Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol 275: H1370-H1374, 1998.
69. SANDERS PW, CHEN PY, GASTON RS, WARNOCK DG: L-arginine and nitric oxide in the regulation of blood pressure. In: Hypertension: Pathophysiology, Diagnosis, and Management JH LARAGH, BM BRENNER (eds), Raven Press, New York, 1995, pp 1097-1098.
70. SCHIFFRIN EL: Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 25: 1135-1143, 1995.
71. SCHLAICH MP, SCHMIEDER RE: Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach. Focus on treatment by antihypertensive agents. Am J Hypertens 11: 1394-1404, 1998.
72. ŠIMKO F: Pathophysiological principles of the relation between myocardial hypertrophy of the left ventricle and its regression. Physiol Res 43: 259-266, 1994.
73. ŠIMKO F: Spontaneous regression of left ventricular hypertrophy in a rabbit model of aortic insufficiency: possible clinical implications. Med Hypotheses 45: 556-558, 1995.
74. ŠIMKO F: Left ventricular hypertrophy regression as a process with variable biological implications. Can J Cardiol 12: 507-513, 1996.
75. ŠIMKO F, ŠIMKO J: Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. Physiol Res 48: 1-8, 1999a.
76. ŠIMKO F, ŠIMKO J: The potential role of nitric oxide (NO) in the hypertrophic growth of the left ventricle. Physiol Res 48: 36P, 1999b.
77. ŠIMKO F, PECHÁŇOVÁ O, BERNÁTOVÁ I, HOLÉCYOVÁ A, ŠIMKO J, SOCHOROVÁ R: Captopril attenuates proteosynthesis in the aorta and decreases endothelaemia in rabbits with aortic insufficiency. Physiol Res 47: 103-107, 1998.
78. ŠIMKO F, PECHÁŇOVÁ O, BERNÁTOVÁ I, PELOUCH V: Effect of angiotensin converting enzyme inhibitors on non-diseased myocardium of experimental animals: potential clinical implications. Med Hypotheses, 2000. (in press)
79. SLÁDEK T, GEROVÁ M, ZNOJIL V, DEVÁT L: Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase. Physiol Res 45: 335-338, 1996.
80. STIER CT Jr, SIM GJ, LEVINE S: Dietary arginine fails to protect against cerebrovascular damage in stroke-prone hypertensive rats. Brain Research 549: 354-356, 1991.
81. SVENTEK P, LI JS, GROVE K, DESCHEPPER CF, SCHIFFRIN EL: Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. Hypertension 27: 49-55, 1996.
82. TADDEI S, VIRDIS A, MATTEI P, SALVETTI A: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 21: 929-933, 1993.
83. TAKAORI K, KIM S, OHTA K, HAMAGUCHI A, YAGI K, IWAO H: Inhibition of nitric oxide synthase causes cardiac phenotypic modulation in rat. Eur J Pharmacol 12: 59-62, 1997.
84. TAKASE H, MOREAU P, KUNG CF, NAVA E, LÜSCHER TF: Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertension 27: 25-31, 1996.
85. TAKEMOTO M, EGASHIRA K, USUI M, NUMAGUCHI K, TOMITA H, TSUTSUI H, SHIMOKAWA H, SUEISHI K, TAKESHITA A: Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99: 278-287, 1997a.
86. TAKEMOTO M, EGASHIRA K, TOMITA T, USUI M, OKAMOTO H, KITABATAKE A, SHIMOKAWA H, SUEISHI K, TAKESHITA A: Chronic angiotensin-converting enzyme inhibition and angiotensin II type I receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 30: 1621-1627, 1997b.
87. UHLENIUS N, TIKKANEN T, MIETTINEN A, HOLTHOFER H, TORNROTH T, ERIKSSON A, FYHRQUIST F, TIKKANEN I: Renoprotective effects of captopril in hypertension induced by nitric oxide synthase inhibition in experimental nephritis. Nephron 81: 221-229, 1999.
88. USUI M, ICHIKI T, KATOH M, EGASHIRA K, TAKESHITA A: Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 32: 527-533, 1998.
89. WATT PAC, THURSTON H: Endothelium-dependent relaxation in resistance vessels from the spontaneously hypertensive rats. J Hypertens 7: 661-666, 1989.
90. WEBER KT, BRILLA CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865, 1991.
91. WICKMAN A, ISGAARD J, ADAMS MA, FRIBERG P: Inhibition of nitric oxide in rats. Regulation of cardiovascular structure and expression of insulin-like growth factor I and its receptor messenger RNA. J Hypertens 15: 751-759, 1997.
92. XU Y, ARNAL JF, HINGLAIS N, APPAY MD, LABOULANDINE I, BARIETY J, MICHEL JB: Renal hypertensive angiopathy. Comparison between chronic NO suppression and DOCA-salt intoxication. Am J Hypertens 8: 167-176, 1995.